{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:24:38Z","timestamp":1777598678030,"version":"3.51.4"},"reference-count":26,"publisher":"Frontiers Media SA","funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"DOI":"10.3389\/fpsyt.2017.00089","type":"journal-article","created":{"date-parts":[[2017,5,22]],"date-time":"2017-05-22T03:41:56Z","timestamp":1495424516000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Behavioral Effects of a Novel Benzofuranyl-Piperazine Serotonin-2C Receptor Agonist Suggest a Potential Therapeutic Application in the Treatment of Obsessive\u2013Compulsive Disorder"],"prefix":"10.3389","volume":"8","author":[{"given":"Michelle M.","family":"Rodriguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl","family":"Overshiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. David","family":"Leander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard G.","family":"Conway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Briner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey M.","family":"Witkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2017,5,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S0193-953X(05)70177-5","article-title":"Quality of life in obsessive\u2013compulsive disorder","volume":"23","author":"Koran","year":"2000","journal-title":"Psychiatr Clin North Am"},{"key":"B2","first-page":"298","article-title":"Biological treatments for obsessive-compulsive disorder. Literature review","volume-title":"Obsessive-Compulsive Disorder: Theory, Research, and Treatment","author":"Pigott","year":"1998"},{"key":"B3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/mp.2008.94","article-title":"The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication","volume":"15","author":"Ruscio","year":"2010","journal-title":"Mol Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.4088\/JCP.14m09670","article-title":"Prevalence and impact of obsessive-compulsive symptoms in depression: a STAR*D report","volume":"76","author":"Baer","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.ebiom.2015.09.006","article-title":"A lifetime prevalence of comorbidity between bipolar affective disorder and anxiety disorders: a meta-analysis of 52 interview-based studies of psychiatric population","volume":"2","author":"Nabavi","year":"2015","journal-title":"EBioMedicine"},{"key":"B6","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.euroneuro.2016.02.004","article-title":"Pharmacoepidemiology of obsessive-compulsive disorder: a Swedish nationwide cohort study","volume":"26","author":"Isomura","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3389\/fnhum.2013.00653","article-title":"The phenomenology of deep brain stimulation-induced changes in OCD: an enactive affordance-based model","volume":"7","author":"de Haan","year":"2013","journal-title":"Front Hum Neurosci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.brainres.2015.12.042","article-title":"Serotonin receptors in brain revisited","volume":"1645","author":"Palacios","year":"2016","journal-title":"Brain Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1001\/archpsyc.1988.01800260081011","article-title":"Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment","volume":"45","author":"Zohar","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/0006-3223(93)90272-F","article-title":"A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to IV mCPP","volume":"33","author":"Pigott","year":"1993","journal-title":"Biol Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0165-1781(91)90113-4","article-title":"Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder","volume":"36","author":"Hollander","year":"1991","journal-title":"Psychiatry Res"},{"key":"B12","first-page":"82","article-title":"A controlled trial of adjunvant clonazepam in clomipramine and fluoxetine treated patients with OCD","author":"Pigott","year":"1992"},{"key":"B13","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0031-9384(03)00047-7","article-title":"Compulsive behavior in the 5-HT2C receptor knockout mouse","volume":"78","author":"Chou-Green","year":"2003","journal-title":"Physiol Behav"},{"key":"B14","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0893-133X(02)00377-9","article-title":"R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis and receptor binding study","volume":"27","author":"Koch","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1124\/jpet.105.089326","article-title":"Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine","volume":"315","author":"Rasmussen","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"B16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1126\/science.133.3447.195","article-title":"Production of polydipsia in normal rats by an intermittent food schedule","volume":"133","author":"Falk","year":"1961","journal-title":"Science"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1016\/j.lfs.2005.08.002","article-title":"Decreases in nestlet shredding of mice by serotonin uptake inhibitors: comparison with marble burying","volume":"78","author":"Li","year":"2006","journal-title":"Life Sci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S0028-3908(97)00038-5","article-title":"SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist","volume":"36","author":"Kennett","year":"1997","journal-title":"Neuropharmacology"},{"key":"B19","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0022-3565(24)37669-4","article-title":"5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential","volume":"286","author":"Martin","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"B20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/sj.bjp.0702751","article-title":"Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells","volume":"128","author":"Porter","year":"1999","journal-title":"Br J Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/0014-2999(94)00698-7","article-title":"The selective 5-HT2A receptor antagonist, MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat","volume":"273","author":"Schmidt","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.bbr.2013.01.005","article-title":"5-HT2C receptor involvement in the control of persistence in the reinforced spatial alternation animal model of obsessive-compulsive disorder","volume":"243","author":"Papakosta","year":"2013","journal-title":"Behav Brain Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.bbr.2014.11.017","article-title":"5-HT2A\/C receptors do not mediate the attenuation of compulsive checking by mCPP in the quinpirole sensitization rat model of obsessive-compulsive disorder (OCD)","volume":"279","author":"Tucci","year":"2015","journal-title":"Behav Brain Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S0028-3908(98)00203-2","article-title":"Discriminative stimulus properties of the novel serotonin (5-HT)2C receptor agonist, RO 60-0175: a pharmacological analysis","volume":"38","author":"Dekeyne","year":"1999","journal-title":"Neuropharmacology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1007\/s00213-016-4329-3","article-title":"Lorcaserin and CP-809101 reduce motor impulsivity and reinstatement of food seeking behavior in male rats: implications for understanding the anti-obesity property of 5-HT2C receptor agonists","volume":"233","author":"Higgins","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/ddr.430200312","article-title":"Analysis of behavioral effects of drugs","volume":"20","author":"Witkin","year":"1990","journal-title":"Drug Dev Res"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fpsyt.2017.00089\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T18:46:50Z","timestamp":1750272410000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fpsyt.2017.00089\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,22]]},"references-count":26,"alternative-id":["10.3389\/fpsyt.2017.00089"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2017.00089","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,22]]},"article-number":"89"}}